← Leaderboards
Scott A. Waldman
Thomas Jefferson University
$27,830,994
Attributed
$31,825,256
Total exposure
18
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,825,256 · 18
By mechanism
R01$17,304,693 · 7
T32$9,738,184 · 2
K30$2,464,028 · 2
RC1$997,134 · 1
R21$548,250 · 2
R25$501,639 · 1
Top collaborators
- Walter K. Kraft9 shared
- Manuel L Covarrubias3 shared
- Kevin James Downes1 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Joshua R Barton$174,828
- Lara Cheslow$179,442
- Erik Blomain$130,062
- Manuel L Covarrubias$9,044,974
- Giovanni M Pitari$154,500
Others in their field
Top investigators on “Colorectal Cancer”
- Norman Wolmark · Nsabp Foundation, Inc.$253,344,814
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$72,920,401
- William J. Blot · Vanderbilt University$60,929,890
- Loic Le Marchand · University Of Hawaii At Manoa$57,327,999
- Ulrike Peters · Fred Hutchinson Cancer Research Center$56,201,247
- Andrew T Chan · Massachusetts General Hospital$47,099,005
Research focus
Colorectal CancerMalignant NeoplasmsMolecularBaseSignal TransductionCellsTranslatingColorectalTranslationsTraining ProgramsPreventProgramsClinical PharmacologyTumorigenesisGeneticIntestinesClinical ResearchFunctional DisorderMediatingReceptorHormonesTumorCancer PreventionTumor Initiation
Grant awards (89)
Targeting visceral pain through intestinal neuropod cell GUCY2C signaling$681,303
R01 · FY2025 · DK · contact PI
Clinical Pharmacology Training Program$592,492
T32 · FY2025 · GM
Clinical Pharmacology Training Program$211,465
T32 · FY2025 · HD
Clinical Pharmacology Training Program$888,184
T32 · FY2024 · GM
Targeting visceral pain through intestinal neuropod cell GUCY2C signaling$654,052
R01 · FY2024 · DK · contact PI
Clinical Pharmacology Training Program$835,075
T32 · FY2023 · GM
Targeting visceral pain through intestinal neuropod cell GUCY2C signaling$722,787
R01 · FY2023 · DK · contact PI
Neuroprotection by the GUCY2C gut-brain axis in Parkinson's disease$429,000
R21 · FY2023 · NS · contact PI
Clinical Pharmacology Training Program$815,600
T32 · FY2022 · GM
Gastrointestinal Cancer$33,003
P30 · FY2022 · CA · contact PI
Clinical Pharmacology Training Program$783,435
T32 · FY2021 · GM
Guanylin GUCY2C axis in Colorectal Cancer Initiation$357,970
R01 · FY2021 · CA · contact PI
Gastrointestinal Cancer$33,003
P30 · FY2021 · CA · contact PI
Clinical Pharmacology Training Program$774,341
T32 · FY2020 · GM
Guanylin GUCY2C axis in Colorectal Cancer Initiation$357,970
R01 · FY2020 · CA · contact PI
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation$356,850
R01 · FY2020 · CA · contact PI
Gastrointestinal Cancer$33,003
P30 · FY2020 · CA · contact PI
Guanylin GUCY2C axis in Colorectal Cancer Initiation$347,230
R01 · FY2019 · CA · contact PI
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation$346,144
R01 · FY2019 · CA · contact PI
Clinical Pharmacology Training Program$322,528
T32 · FY2019 · GM · contact PI
Gastrointestinal Cancer$33,003
P30 · FY2019 · CA · contact PI
Clinical Pharmacology Training Program$636,774
T32 · FY2018 · GM · contact PI
Guanylin GUCY2C axis in Colorectal Cancer Initiation$357,970
R01 · FY2018 · CA · contact PI
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation$356,850
R01 · FY2018 · CA · contact PI
Gastrointestinal Cancer$33,003
P30 · FY2018 · CA · contact PI
Gastrointestinal Cancer$11,841
P30 · FY2018 · CA · contact PI
Clinical Pharmacology Training Program$519,705
T32 · FY2017 · GM · contact PI
Guanylin GUCY2C axis in Colorectal Cancer Initiation$371,970
R01 · FY2017 · CA · contact PI
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation$356,850
R01 · FY2017 · CA · contact PI
Clinical Pharmacology Training Program$442,419
T32 · FY2016 · GM · contact PI
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation$356,850
R01 · FY2016 · CA · contact PI
GUCY2C hormone signaling at the intersection of obesity and colorectal cancer(PQ1$321,625
R01 · FY2015 · CA · contact PI
Clinical Pharmacology Training Program$139,608
T32 · FY2015 · GM · contact PI
GUCY2C hormone signaling at the intersection of obesity and colorectal cancer(PQ1$311,976
R01 · FY2014 · CA · contact PI
Clinical Pharmacology Training Program$73,213
T32 · FY2014 · GM · contact PI
GUCY2C hormone signaling at the intersection of obesity and colorectal cancer(PQ1$302,328
R01 · FY2013 · CA · contact PI
Clinical Pharmacology Training Program$288,130
T32 · FY2013 · GM · contact PI
GUCY2C hormone signaling at the intersection of obesity and colorectal cancer(PQ1$321,625
R01 · FY2012 · CA · contact PI
Clinical Pharmacology Training Program$275,072
T32 · FY2012 · GM · contact PI
Gastro Intestinal Cancer$30,359
P30 · FY2012 · CA · contact PI
Clinical Pharmacology Training Program$261,510
T32 · FY2011 · GM · contact PI
Gastro Intestinal Cancer$31,130
P30 · FY2011 · CA · contact PI
Occult lymph node metastases and racial disparities in colon cancer outcomes$498,629
RC1 · FY2010 · CA · contact PI
Clinical Pharmacology Training Program$263,752
T32 · FY2010 · GM · contact PI
Gastro Intestinal Cancer$32,983
P30 · FY2010 · CA · contact PI
Occult lymph node metastases and racial disparities in colon cancer outcomes$498,505
RC1 · FY2009 · CA · contact PI
Training Program in Human Investigation$300,000
K30 · FY2009 · RR · contact PI
Clinical Pharmacology Training Program$121,998
T32 · FY2009 · GM · contact PI
Guanylyl Cyclase C in Blood and Colorectal Cancer$835,938
R01 · FY2008 · CA · contact PI
Training Program in Human Investigation$300,000
K30 · FY2008 · RR · contact PI
Clinical Pharmacology Training Program$224,355
T32 · FY2008 · GM · contact PI
Guanylyl Cyclase C in Blood and Colorectal Cancer$669,957
R01 · FY2007 · CA · contact PI
Training Program in Human Investigation$300,000
K30 · FY2007 · RR · contact PI
Clinical Pharmacology Training Program$116,872
T32 · FY2007 · GM · contact PI
Short-term Training Program in Translational Cancer Rese$88,181
R25 · FY2007 · CA · contact PI
Guanylyl Cyclase C in Blood and Colorectal Cancer$54,169
R01 · FY2007 · CA · contact PI
GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER$1,026,076
R01 · FY2006 · CA · contact PI
Training Program in Human Investigation$300,000
K30 · FY2006 · RR · contact PI
Clinical Pharmacology Training Program$215,788
T32 · FY2006 · GM · contact PI
Short-term Training Program in Translational Cancer Rese$88,712
R25 · FY2006 · CA · contact PI
Guanylyl Cyclase C in Blood and Colorectal Cancer$44,707
R01 · FY2006 · CA · contact PI
Guanylyl Cyclase C in Blood and Colorectal Cancer$1,369,727
R01 · FY2005 · CA
GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER$1,069,881
R01 · FY2005 · CA
Training Program in Human Investigation$300,000
K30 · FY2005 · RR
Clinical Pharmacology Training Program$226,454
T32 · FY2005 · GM
Short-term Training Program in Translational Cancer Rese$88,758
R25 · FY2005 · CA
Guanylyl Cyclase C in Blood and Colorectal Cancer$1,204,316
R01 · FY2004 · CA
GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER$1,044,444
R01 · FY2004 · CA
TRAINING PROGRAM IN HUMAN INVESTIGATION$199,999
K30 · FY2004 · HL
CLINICAL PHARMACOLOGY TRAINING PROGRAM$142,589
T32 · FY2004 · GM
Short-term Training Program in Translational Cancer Rese$86,728
R25 · FY2004 · CA
GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER$975,547
R01 · FY2003 · CA
Guanylyl Cyclase C in Blood and Colorectal Cancer$943,213
R01 · FY2003 · CA
TRAINING PROGRAM IN HUMAN INVESTIGATION$196,940
K30 · FY2003 · HL
CLINICAL PHARMACOLOGY TRAINING PROGRAM$187,660
T32 · FY2003 · GM
Short-term Training Program in Translational Cancer Rese$70,375
R25 · FY2003 · CA
GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER$991,217
R01 · FY2002 · CA
TRAINING PROGRAM IN HUMAN INVESTIGATION$193,970
K30 · FY2002 · HL
CLINICAL PHARMACOLOGY TRAINING PROGRAM$186,338
T32 · FY2002 · GM
CORE--DEVELOPMENTAL THERAPEUTICS$0
P30 · FY2002 · CA
TRAINING PROGRAM IN HUMAN INVESTIGATION$191,087
K30 · FY2001 · HL
CLINICAL PHARMACOLOGY TRAINING PROGRAM$87,294
T32 · FY2001 · GM
SHORT TERM TRAINING PROGRAM--TRANSLATIONAL CANCER RESEAR$41,625
R25 · FY2001 · CA
CORE--DEVELOPMENTAL THERAPEUTICS$0
P30 · FY2001 · CA
ALLOSTERIC INHIBITION OF GUANYLYL CYCLASE BY NUCLEOTIDES$193,151
R01 · FY2000 · HL
TRAINING PROGRAM IN HUMAN INVESTIGATION$182,032
K30 · FY2000 · HL
GUANYLYL CYCLASE C IN BLOOD AND COLORECTAL CANCER$119,250
R21 · FY2000 · CA
CLINICAL PHARMACOLOGY TRAINING PROGRAM$105,533
T32 · FY2000 · GM
SHORT TERM TRAINING PROGRAM--TRANSLATIONAL CANCER RESEAR$37,260
R25 · FY2000 · CA